Please use this identifier to cite or link to this item:
Title: Erectile function following transperineal prostate biopsy: a prospective longitudinal study of 170 patients.
Epworth Authors: Landau, Adam
Moon, Daniel
Frydenberg, Mark
Grummet, Jeremy
Other Authors: Ronan, Lewis
Mann, Sarah
Huang, Sean
Snow, Ross
Hanegbi, Uri
Keywords: Erectile Dysfunction
Prostate Biopsy
Transperineal Prostate Biopsy
Erectile Function
Sexual Health Inventory for Men
SHIM Questionnaire
Epworth Prostate Cancer Research Centre, Epworth HealthCare, Victoria, Australia
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Jul-2016
Conference: ANZUP Annual Scientific Meeting, GU Cancer: Expanding our Horizons, 10–12 July 2016
Conference Location: Hilton Brisbane Queensland.
Abstract: INTRODUCTION & OBJECTIVES: Data on erectile dysfunction (ED) associated with prostate biopsy is limited and heterogeneous. Transperineal prostate biopsy (TPB) has increasingly been utilized by Urologists due to negligible rates of sepsis combined with better sampling of the prostate. This study aims to evaluate the impact of TPB on erectile function. METHOD: All patients undergoing TPB at a private group practice of seven Urologists were enrolled in this ethics approved study. Patients were provided the validated Sexual Health Inventory for Men (SHIM) questionnaire (aka IIEF-5) at pre-biopsy and at 1, 3, and 12 months follow-up. Patients who had undergone subsequent treatment including prostatectomy, radiation, or androgen deprivation therapy, were excluded from analysis. RESULTS: Between October 2013 and May 2015, 170 patients had completed a baseline SHIM questionnaire and at least one other follow-up SHIM questionnaire. The mean age was 63.3 years (SD 7.2), mean pre-biopsy PSA was 7.8 ng/mL (SD 0.8) and median number of biopsy cores taken was 24 (IQR 22–24). Within this cohort, 60% (102/170) had initial biopsies, 11.1% (19/170) had previous negative TRUS biopsies and 28.9% (49/1770) had their biopsy as part of active surveillance. A total of 156 (91.8%), 30 (17.6%), and 38 (22.4%) patients had recorded baseline and follow-up SHIM questionnaires at 1, 3 and 12 months, respectively. The mean change in SHIM scores between baseline and follow-up was −2.18 (P < 0.001), −2.77 (P = 0.0154), and −1.29 (P = 0.0061) after 1, 3, and 12 months, respectively. There was no statistically significant difference between patients diagnosed with cancer and those without cancer diagnosis at any stage of follow-up. CONCLUSIONS: There appears to be a mild reduction in erectile function after TPB. Although this effect is mild and improves over time, patients should be counselled regarding this possible outcome prior to biopsy.
DOI: 10.1111/ajco.12558
Type: Conference Poster
Affiliated Organisations: Monash University, Melbourne, Victoria, Australia.
Type of Clinical Study or Trial: Prospective Study
Appears in Collections:Cancer Services
UroRenal, Vascular
Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.

Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.